Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by RTW Investments LP

RTW Investments LP lessened its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,218,641 shares of the company’s stock after selling 1,600,000 shares during the quarter. Dyne Therapeutics comprises about 1.9% of RTW Investments LP’s investment portfolio, making the stock its 21st biggest position. RTW Investments LP owned about 0.05% of Dyne Therapeutics worth $122,951,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Rafferty Asset Management LLC increased its position in shares of Dyne Therapeutics by 1.5% during the fourth quarter. Rafferty Asset Management LLC now owns 167,482 shares of the company’s stock worth $3,946,000 after acquiring an additional 2,520 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Dyne Therapeutics by 802.3% during the fourth quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company’s stock worth $21,785,000 after acquiring an additional 822,201 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Dyne Therapeutics by 32.4% during the fourth quarter. ProShare Advisors LLC now owns 28,044 shares of the company’s stock worth $661,000 after acquiring an additional 6,862 shares during the last quarter. Man Group plc grew its stake in Dyne Therapeutics by 3.9% in the fourth quarter. Man Group plc now owns 746,463 shares of the company’s stock worth $17,587,000 after purchasing an additional 27,813 shares in the last quarter. Finally, Orbimed Advisors LLC grew its stake in Dyne Therapeutics by 73.2% in the fourth quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company’s stock worth $28,910,000 after purchasing an additional 518,680 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Ratings Changes

DYN has been the subject of a number of research reports. HC Wainwright decreased their price target on Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 9th. Piper Sandler decreased their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, BMO Capital Markets initiated coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.85.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 6,237 shares of company stock valued at $77,760 in the last quarter. Insiders own 14.14% of the company’s stock.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $11.74 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $47.45. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -3.30 and a beta of 1.19. The firm’s 50 day moving average price is $10.37 and its two-hundred day moving average price is $17.64.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.